Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Tags, ,

Journal: Blood advances

This retrospective two-center study evaluated how quantitative NPM1-mutated MRD levels around allogeneic transplant predict outcomes and might guide interventions in NPM1-mutated AML.

Key points:

  • Population: 172 adults with NPM1-mutant AML undergoing allogeneic hematopoietic cell transplantation, with serial NPM1-MRD monitoring pre- and post-transplant.
  • Pre-transplant MRD:
    • MRD negativity before transplant was a strong predictor of favorable long-term overall survival.
    • This prognostic impact was more informative than traditional factors such as age, FLT3-ITD status, or morphological remission status.
  • Early post-transplant MRD (day +30):
    • Binary MRD status at day 30 (positive vs negative) alone did not discriminate overall survival; patients with positive and negative MRD had comparable OS when considered only by this simple cut-off.
  • Quantitative MRD thresholds and composite scores:
    • The investigators identified statistically derived quantitative NPM1-MRD thresholds that separated patients into MRD-high and MRD-low groups with clearly different outcomes.
    • They built two longitudinal MRD-based risk scores:
    • Early score (pre-HCT + day 30 MRD):
      • Intended to inform early decisions such as intensity and timing of immunosuppression taper.
      • Showed good discrimination (C-index 0.737).
    • Extended score (pre-HCT + day 30 + day 100 MRD):
      • Aimed to guide later post-transplant strategies (e.g., maintenance/relapse-prevention approaches).
      • Showed stronger prognostic performance (C-index 0.841).
      • Defined four risk groups with markedly different 2-year OS (100%, 90.1%, 57.1%, and 25.7%; P < .0001).
  • Overall conclusion:
    • Quantitative, threshold-based, and longitudinal NPM1-MRD assessment in the peri-transplant period is more informative than:
      • Simple MRD-positive vs -negative categorization, or
      • Crude log-fold changes alone, or
      • Standard clinical variables (age, FLT3-ITD, morphology).
    • Such refined MRD-based scoring could rationally direct immunosuppression tapering and other post-transplant interventions in NPM1-mutated AML.

Leave a Reply